Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products.